Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Vertex Pharmaceuticals Incorporated (NASDAQ ... and is pioneering treatments for T1D, including VX-880, a stem cell-derived therapy aimed at restoring insulin production. Clinical trials have ...

such as VX-548 for chronic pain and VX-880 for type 1 diabetes, will be crucial in determining Vertex's long-term prospects beyond CF. While Vertex currently holds a commanding position in the CF ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...

Vertex is also evaluating VX-880 in a phase 3 study as a potential cure for severe type 1 diabetes. Fourth, I expect Vertex will likely further expand its pipeline through business development deals.

The current data for VX-880, as you know, which is in pivotal development ... the device was invented by our team was at Semma, now Vertex that are still all there as the device has novel ...

Vertex Pharmaceuticals Incorporated ... treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of ...

Vertex Pharmaceuticals (Nasdaq ... Meanwhile, a recent clinical trial of VX-880, a stem cell-derived treatment for type-1 diabetes, has shown encouraging results after six months – nine of ...